May 2, 2025, 18:25
LOXHD1 Identified as Immunotherapy Target in Ewing Sarcoma – Parker Institute for Cancer Immunotherapy
Parker Institute for Cancer Immunotherapy shared a post on X:
“Few cancers rob young lives of time like Ewing sarcoma. New Scientific Reports research led by PICI Investigator Beatriz Carreno, PhD (Penn Medicine), with contributions from Gerald P. Linette, MD, PhD, and Carl June, MD, reveals LOXHD1 as a tumor-specific target for immunotherapy. Supported by Parker Institute for Cancer Immunotherapy.”
Title: LOXHD1 is an oncofusion-regulated antigen of Ewing sarcoma
Authors: Tatiana Blanchard, Pouya Faridi, Chong Xu, Adham S. Bear, Reyaz ur Rasool, Grace Huang, Terry C. C. Lim, Rochelle Ayala, Khatuna Gabunia, Mei Ji, Avery D. Posey Jr, John Scholler, Irfan A. Asangani, Anthony W. Purcell, Gerald P. Linette, Carl H. June and Beatriz M. Carreno.
You can read the Full Article on Scientific Reports.
Read about Ewing Sarcoma on OncoDaily.
More posts featuring Parker Institute for Cancer Immunotherapy.
Adham S. Bear
Anthony W. Purcell
Avery D. Posey Jr
Beatriz M. Carreno
cancer
Carl H. June
Carl June
Chong Xu
Ewing sarcoma
Gerald P. Linette
Grace Huang
immunotherapy
Irfan A. Asangani
John Scholler
Khatuna Gabunia
LOXHD1
Mei Ji
OncoDaily
Oncology
Parker Institute for Cancer Immunotherapy
Pouya Faridi
Reyaz ur Rasool
Rochelle Ayala
Scientific Reports
Tatiana Blanchard
Terry C. C. Lim
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 2, 2025, 18:20
May 2, 2025, 18:13
May 2, 2025, 17:59
May 2, 2025, 17:48
May 2, 2025, 17:41
May 2, 2025, 17:37
May 2, 2025, 17:29